

IN THE CLAIMS

Claim 1 (Currently Amended): An SP-C analog having general formula (I) (~~SEQ ID NO: 1~~), according to one letter

~~amino acid code:~~

F_eG_fIPZZPVHLKR(X_aB)(X_bB)_n(X_cB)_mX_dGALLMGL (SEQ ID NO: 1)

wherein:

X is an amino acid selected from the group consisting of I, L, and Nle (norleucine);

B is an amino acid selected from the group consisting of K, W, F, Y, and Ornithine;

wherein

Z is S (Ser) and can be optionally linked via an ester or thio-ester bonds with an acyl group containing 12-22 carbon atoms;

a is an integer from 1 to 19;

b is an integer from 1 to 19;

c is an integer from 1 to 21;

d is an integer from 0 to 20;

~~e is 0 or 1;~~

~~f is 0 or 1;~~

e = f = 0 or 1;

n is 0 or 1;

m is 0 or 1;

with the following conditions:

~~n+m>0;~~

~~f ≥ e;~~

(X_aB)(X_bB)_n(X_cB)_mX_d is a sequence having a maximum of 22 amino acids.

Claim 2 (Currently Amended): An SP-C analogues according to claim 1, having formula (Ia): (1a) (~~SEQ ID NO:2~~)

(1a) FGIPSSPVHLKRX₄BX₄BX₄BXGALLMGL (SEQ ID NO: 2).

Claim 3 (Currently Amended): An SP-C analogues according to claim 1, having formula (Ib): (~~SEQ ID NO:3~~)

(1b) FGIPSSPVHLKRX₅BX₅BX₄GALLMGL (SEQ ID NO: 3).

Claim 4 (Currently Amended): SP-C analogues according to claim 1, having formula (Ic): (~~SEQ ID NO:4~~)

(1c) FGIPSSPVHLKRX₄BX₁₁GALLMGL (SEQ ID NO: 4).

Claim 5 (Currently Amended): An SP-C analogues according to claim 1, having formula (Id): (~~SEQ ID NO:5~~)

(1d) FGIPSSPVHLKRX₈BX,GALLMGL (SEQ ID NO: 5).

Claim 6 (Currently Amended): An SP-C analogues according to claim 1, having formula (Ie): (~~SEQ ID NO:6~~)

(1e) FGIPSSPVHLKRX₁₁BX₄GALLMGL (SEQ ID NO: 6).

Claim 7 (Currently Amended): An SP-C analog according to ~~claim 1~~, in which Ser residues are acylated.

Claim 8 (Currently Amended): An SP-C analog according to ~~claim 1~~, in which B is Lysine or Phenylalanine and X is Leucine, Isoleucine or Norleucine.

Claim 9 (Currently Amended): An SP-C analogues according to claim 8, selected from the group consisting of:

SP-C (LKS) FGIPSSPVHLKRLILKLLLLKILLKLGALLMGL (SEQ ID NO: 7);

SP-C (LKS)₁ FGIPSSPVHLKRLILLKLLLKLLIKLLILGALLMGL (SEQ ID NO: 8);

SP-C (LKS)₂ FGIPSSPVHLKRLILKLLLLLILLLILGALLMGL (SEQ ID NO: 9);

SP-C (LKS)₃ FGIPSSPVHLKRLILLLLLKLILLILGALLMGL (SEQ ID NO: 10);

SP-C (LKS)₄ FGIPSSPVHLKRLILLLLLLILKLLILGALLMGL (SEQ ID NO: 11);

and

SP-C (LFS) FGIPSSPVHLKRLILFLLLFLILLFLGALLMGL (SEQ ID NO: 12).

Claim 10 (Currently Amended): A synthetic surfactant comprising at least one SP-C analogue ~~as claimed in or~~ claim 1 in admixture with at least one lipids and/or phospholipids.

Claim 11 (Currently Amended): A synthetic surfactant according to ~~claim 9~~ claim 10, in which ~~the mixture lipids/phospholipids~~ said lipids and/or phospholipids comprises DPPG, PG, and/or PA.

Claim 12 (Previously Presented): A synthetic surfactant according to ~~claim 10~~ claim 10, further comprising SP-B or an active derivative thereof, or a polymyxin.

Claim 13 (Currently Amended): A synthetic surfactant according to ~~claim 10~~ claim 10, in the form of a solution, dispersion, suspension, or a dry powder.

Claims 14-16 (Canceled).

Claim 17 (Currently Amended): The SP-C analogue as claimed in of claim 1 wherein the $(X_aB)(X_bB)_n(X_cB)_mX_d$ sequence has from 10 to 22 amino acids.

Claim 18 (Currently Amended): The SP-C analogue as claimed in of claim 7 wherein the Ser residues are acylated with palmitoyl groups.

Claim 19 (Currently Amended): A pharmaceutically active synthetic surfactant comprising the SP-C analogues of claim 1.

Claim 20 (Withdrawn, Currently Amended): A method of treating a surfactant deficiency comprising administering an effective amount of the SP-C analogues of claim 1 to a subject in need thereof.

Claim 21 (Currently Amended): A pharmaceutically active synthetic surfactant comprising the surfactant of claim 10, wherein said surfactant comprises polymyxin.

Claim 22 (Currently Amended): A pharmaceutically active synthetic surfactant comprising the surfactant of claim 10, wherein said surfactant comprises polymyxin B.

Claim 23 (Withdrawn, Currently Amended): A method of treating surfactant deficiencies or dysfunction, or serious otitis media, comprising administering an effective amount of the surfactant of claim 10 to a subject in need thereof, wherein said surfactant comprises polymyxin.

Claim 24 (Withdrawn, Currently Amended): A method of treating a surfactant deficiency or dysfunction, or serious otitis media, comprising administering to a subject in need thereof an effective amount of the surfactant of Cclaim 10 wherein said surfactant comprises polymyxin B.

Claim 25 (Withdrawn, Currently Amended): The method of treating a surface deficiency of Cclaim 20, wherein said surfactant deficiency is subject has respiratory distress syndrome.

Claim 26 (Withdrawn, Currently Amended): The method of treating a surface deficiency of Cclaim 23, wherein said surfactant deficiency is subject has respiratory distress syndrome.

Claim 27 (Withdrawn, Currently Amended): The method of treating a surface deficiency of Cclaim 24, wherein said surfactant deficiency is subject has respiratory distress syndrome.

28 (New): The SP-C analog of claim 1, wherein B is selected from the group consisting of K, F and I.

29 (New): The SP-C analog of claim 1, wherein X is selected from the group consisting of I and L.

30 (New): The SP-C analog of claim 1, wherein B is selected from the group consisting of K, F and I; and X is selected from the group consisting of I and L.

31 (New): A pharmaceutically active synthetic surfactant comprising the surfactant of claim 10, wherein said surfactant of claim 10 contains at least one phospholipid selected from the group consisting of DPPC and PG.

32 (New): A method of treating a surfactant deficiency or dysfunction or serious otitis media, comprising:

administering to a subject in need thereof an effective amount of the surfactant of claim 10, wherein said surfactant of claim 10 contains at least one phospholipid selected from the group consisting of DPPC and PG.